Galliprant is not a traditional NSAID. It belongs to a newer drug class called piprants, which work through a fundamentally different mechanism than conventional anti-inflammatory drugs like carprofen or meloxicam. While Galliprant treats the same core problem in dogs (pain and inflammation from osteoarthritis), it gets there by a different biological route, and that distinction matters for your dog’s safety.
How Galliprant Differs From Traditional NSAIDs
Traditional NSAIDs work by blocking enzymes called COX-1 and COX-2. These enzymes produce a family of chemical messengers called prostaglandins, which play roles in inflammation, pain, and also in normal body functions like protecting the stomach lining and maintaining kidney blood flow. When a traditional NSAID shuts down COX enzymes, it reduces inflammation but also cuts off those protective functions. That’s why conventional NSAIDs can cause gastrointestinal upset, kidney problems, and liver stress in some dogs.
Galliprant (the brand name for grapiprant) takes a more targeted approach. Instead of blocking the production of all prostaglandins, it blocks just one specific receptor called EP4. This receptor is the primary driver of pain sensitization and inflammation triggered by a particular prostaglandin, PGE2. By blocking only EP4, Galliprant leaves other prostaglandin pathways intact, meaning the protective functions those molecules perform elsewhere in the body are better preserved.
Think of it this way: traditional NSAIDs cut off the supply of a chemical that has both harmful and helpful roles. Galliprant lets the chemical be produced normally but blocks it from activating the specific receptor responsible for pain and inflammation.
What Galliprant Is Approved For
The FDA approved Galliprant in 2016 specifically for the control of pain and inflammation associated with osteoarthritis in dogs. The European Medicines Agency followed in 2018, approving it for pain management. It’s given as a once-daily tablet at a dose of 2 mg/kg (about 0.9 mg per pound of body weight), ideally on an empty stomach.
This is a canine medication. It is not approved for cats, and at least one study found it did not provide adequate pain control in cats after surgery, with 67% of cats treated with grapiprant requiring additional pain relief compared to only 18% of those given carprofen.
Safety Profile and Side Effects
One of the main reasons veterinarians reach for Galliprant is its safety profile relative to traditional NSAIDs, particularly for long-term use. A nine-month toxicity study in dogs confirmed that grapiprant at the standard 2 mg/kg daily dose was safe for extended administration.
At much higher doses (up to 25 times the recommended amount in the toxicity study), dogs did develop gastrointestinal signs like soft or watery stools, sometimes with mucus or blood, along with vomiting. Higher doses also caused mild, reversible drops in blood protein levels, specifically albumin and total protein. These changes resolved once the drug was discontinued, and they were dose-dependent, meaning they were far less likely at the standard prescribed dose.
The most common side effects dog owners notice at normal doses are mild vomiting, diarrhea, and decreased appetite. These tend to be less severe than the gastrointestinal problems associated with traditional NSAIDs, though individual dogs vary.
Which Dogs Are Good Candidates
Galliprant is used across a wide range of dogs. In the pivotal clinical study that led to FDA approval, treated dogs ranged from 2 to nearly 17 years old and weighed between about 9 and 131 pounds. Dogs with stable chronic conditions were included in the study, meaning Galliprant was evaluated in the kinds of older, sometimes medically complex dogs that commonly develop osteoarthritis.
Dogs with pre-existing kidney or liver concerns are often where the choice between Galliprant and a traditional NSAID becomes most relevant. Because Galliprant doesn’t broadly suppress prostaglandin production, it may carry less risk to organs that depend on those protective pathways. Your veterinarian can evaluate bloodwork to determine which option makes sense for your dog’s specific situation.
Galliprant With Other Medications
Galliprant should not be combined with traditional NSAIDs or corticosteroids. Using two anti-inflammatory drugs simultaneously increases the risk of gastrointestinal ulceration and other serious side effects. If your dog is switching from a traditional NSAID to Galliprant (or vice versa), a washout period between the two medications is standard practice. Your vet will determine the appropriate gap based on which drug your dog was previously taking and how long it takes to clear the body.
Is It Less Effective Than a Traditional NSAID?
The targeted mechanism that makes Galliprant gentler also raises the question of whether it’s as powerful. For osteoarthritis pain in dogs, clinical studies supported its approval as effective. But for acute surgical pain, the picture is different. The cat surgery study mentioned earlier highlights that grapiprant may not match the raw analgesic power of a COX-2 inhibitor like carprofen in certain high-pain scenarios. This is partly why Galliprant is specifically indicated for the chronic, ongoing pain of osteoarthritis rather than acute post-surgical pain.
For the typical dog owner managing a pet with joint pain, Galliprant offers a meaningful option that balances pain control with a more favorable side effect profile. It occupies a distinct space from traditional NSAIDs, and understanding that it works differently (not just “more gently”) helps explain both its advantages and its limitations.